Colorectal Cancer is a new Decision Resources study that evaluates emerging trends in the treatment of this highly prevalent disease. We believe that an increase in drug treatment rates, new therapeutics suitable for larger numbers of patients, and greater use of expensive drugs will drive substantial growth in colorectal cancer (CRC) drug sales in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) through 2010.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

For years, 5-FU was the only chemotherapy agent available to treat CRC. However, with the introduction of the topoisomerase inhibitors and new platinum compounds, which have produced an increase in survival rates, the treatment of CRC has moved into a new era. Our analysis of emerging therapies includes the following:

  -- The most likely agents to have a positive effect on CRC therapy in the      next five to ten years are oral fluorouracil-based therapies and      thymidylate synthase inhibitors. Of this group, the front-runner is      capecitabine (Hoffmann-La Roche's Xeloda), a fluorouracil pro-drug.      Essentially an improved version of 5-FU but in oral form, capecitabine      was approved by the European Commission in February 2001 and by the      U.S. FDA in May 2001. Thought leaders interviewed for this study assert      that, compared with 5-FU, capecitabine promises the advantages of      convenience and an improved side-effect profile   -- We expect Bristol-Myers Squibb's Orzel (an orally active combination of      the tegafur-uracil/leucovorin [UFT/LV] cocktail) to have a substantial      impact on the CRC market despite the FDA's March 2001 issuance of a      "not approvable" letter. Our optimism is based on Bristol-Myers      Squibb's stated determination to continue to pursue approval, and      Orzel's approval in Europe.   -- We expect one or two emerging biological therapies such as vaccines and      vascular endothelial growth factor receptor therapies to make it to      market for refractory metastatic CRC by 2010. We believe that these      therapies will be supplemental to other drug therapies.  

Colorectal Cancer offers invaluable market intelligence for pharmaceutical companies developing drugs to treat this indication. This study is part of Onkos, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.

Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or sama@dresources.com. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or fbidart@decisionresources.be. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X41957653

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, 781-296-2553,
sama@dresources.com

Decision Resources Publishes Genomics and Drug Development: Impacts and Strategic Implications

View Now